US regulatory status: approved.
pharma · Myotonic Dystrophy Type 1 · Myotonic Dystrophy Type 1 (DM1) · DYN
Dyne Therapeutics
Dyne Therapeutics drug portfolio — 11 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Waltham, USA HQ
2018 Founded
276 Employees
Public company Type
DYN · NYSE Ticker
Company details
- Status
- Public
- HQ
- Waltham, USA
- Founded
- 2018
- Employees
- 276
- Programs
- 6
- Drugs
- 11
- Patents
- 82
Dyne Therapeutics pipeline
Portfolio lens on 11 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Dyne Therapeutics drug portfolio — 11 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Dyne Therapeutics in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to Dyne Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
US regulatory status: approved. Molecular target: Mu-type opioid receptor.
- Target
- Mu-type opioid receptor
- Mechanism
- Mu opioid receptor agonist
-
Development asset linked to Dyne Therapeutics in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to Dyne Therapeutics in public FDA and regional records.
-
Development asset linked to Dyne Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent